Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Lenvatinib and Chemotherapy in TKI-Refractory NSCLC
NCT04989322Phase 2Unknown
- Start
- Oct 2021
- Primary completion
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lenvatinib in non-small cell lung cancer (NSCLC). Primary endpoint: Overall Response Rate at 24 months. Status: unknown.
02
Drugs
pembrolizumablenvatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04989322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04989322.